Gillian Vandekerkhove, PhD, of the University of British Columbia, discusses her latest research on genomic testing in prostate cancer, including timing recommendations and a discussion on the role of interdisciplinary collaborations. Dr. Vandekerkhove also explains how socioeconomic factors impact the utilization of genomic testing in prostate cancer diagnosis and treatment as well as the primary obstacles to standardizing the reporting in genomic testing. ...
Prostate Cancer Diagnostics
Advertisement
Latest News
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
